Category Archives: Healthcare

Maxim Group Reaffirms Their Buy Rating on Cassava Sciences Inc (SAVA)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Cassava Sciences Inc (SAVA – Research Report) yesterday and set a price target of $3. The company’s shares closed last Monday at $1.30. McCarthy wrote: “Cassava announced the initiation of

Cowen & Co. Keeps a Buy Rating on Stemline Therapeutics Inc (STML)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report). The company’s shares closed last Monday at $10.83. According to TipRanks.com, Peaker is a 3-star analyst with

Needham Keeps a Buy Rating on Zimmer Biomet Holdings (ZBH)

Needham analyst Michael Matson maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) today and set a price target of $170. The company’s shares closed last Monday at $138.84, close to its 52-week high of $143.57. According

The CFO & EVP of Ultragenyx Pharmaceutical, Inc. is Exercising Options

Yesterday it was reported that the CFO & EVP of Ultragenyx Pharmaceutical, Inc. (RARE – Research Report), Shalini Sharp, exercised options to buy 31,843 RARE shares at $5.53 a share, for a total transaction value of $176.3K. Following this transaction

A Director at Lexicon Pharmaceuticals (NASDAQ: LXRX) is Buying Shares

Yesterday, a Director at Lexicon Pharmaceuticals (LXRX – Research Report), Raymond Debbane, bought shares of LXRX for $474.7K. This recent transaction increases Raymond Debbane’s holding in the company by 4.77% to a total of $13.63 million. In addition to Raymond

Stifel Nicolaus Reiterates Their Buy Rating on Esperion (ESPR)

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Esperion (ESPR – Research Report), with a price target of $70. The company’s shares closed last Monday at $36.78, close to its 52-week low of